HMB, or β-hydroxy β-methylbutyrate, is a leucine-derived metabolite produced in small amounts during normal human amino-acid metabolism and studied mainly for muscle preservation, resistance-training adaptation, sarcopenia-related outcomes, and catabolic illness contexts. (Review)
HMB research is most developed in Muscle Health, especially resistance training, exercise-related muscle damage, aging-related muscle function, and inactivity-related muscle loss. Human findings are mixed: some studies report favorable effects in untrained, older, inactive, or catabolic populations, while trials in trained athletes often report little or no added effect. (Review) (Review) The most common supplemental research dose is 3 g/day, while pharmacokinetic studies have used 1 g single-dose comparisons to evaluate timing and formulation differences between calcium-HMB and HMB free acid. (Research) (Research)
Ingredient Identity
- Official name(s): β-hydroxy β-methylbutyrate; 3-hydroxy-3-methylbutyric acid. (FDA)
- Synonyms: HMB; beta-hydroxy-beta-methylbutyrate; beta-hydroxyisovaleric acid. (FDA)
- Classification: HMB is a metabolite of the branched-chain amino acid leucine. (Review)
- CAS number: 625-08-1 for 3-hydroxy-3-methylbutyric acid is listed in substance-registration records. (FDA)
- Endogenous vs exogenous: HMB is produced endogenously from leucine metabolism and is also used exogenously in supplemental forms such as calcium-HMB and HMB free acid. (Review) (Research)
Ingredient Snapshot
- Classification: Leucine metabolite studied in sports nutrition, aging, physical function, and clinical nutrition research. (Review)
- Endogenous vs exogenous status: Humans produce small amounts of HMB from leucine, while human studies usually use supplemental gram-level exposures. (Review)
- Primary human research domains: The main human research domains are Muscle Health, Aging and Longevity Research, Nutrition and Deficiencies, Cancer Research, and Liver Health. (Review) (Review)
- Common study formats: Human studies include resistance-training trials, bed-rest studies, older-adult trials, pharmacokinetic crossover studies, ICU studies, clinical nutrition trials, and systematic reviews or meta-analyses. (Research) (Review)
- Pharmacokinetic characterization status: HMB has human pharmacokinetic data showing that oral HMB generally reaches peak blood levels within about 40–130 minutes, depending on formulation and study design. (Research) (Research)
- Regulatory context: FDA substance records identify HMB-related chemical names, and FDA New Dietary Ingredient records include a notification involving beta-hydroxy-beta-methylbutyrate-L-arginine. (FDA) (FDA)
- EU regulatory context: EFSA reviewed proposed health claims for beta-hydroxy beta-methylbutyrate monohydrate and evaluated claims related to muscle and resistance-training outcomes. (EFSA)
- Evidence maturity: The evidence base is moderate in volume but mixed in consistency, with stronger signals in selected untrained, older, inactive, or catabolic populations and weaker evidence in trained athletes. (Review) (Review)
Introduction
HMB is formed when the body metabolizes leucine, an essential branched-chain amino acid found in protein-containing foods. Only a small fraction of leucine is converted into HMB, so endogenous HMB production is much lower than the gram-level exposures used in many supplementation studies. (Review)
People commonly look up HMB because it has been studied for muscle preservation, resistance-training adaptation, exercise-related muscle damage, sarcopenia, inactivity-related muscle loss, and clinical catabolic states. Human research has attracted interest because results appear to differ by training status, age, baseline muscle condition, formulation, co-interventions, and illness context. (Review) (Review)
This article is informational only, describes HMB as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- HMB is a leucine metabolite studied mainly for Muscle Health, including resistance training, muscle preservation, muscle damage markers, lean mass, strength, and physical function. (Review) (Review)
- Human evidence is most favorable in selected untrained, older, inactive, or catabolic populations, while trained-athlete studies often report little or no added strength or body-composition effect. (Review) (Review)
- Resistance-training trials commonly use 3 g/day HMB, although human studies have also used 1.5 g/day and 6 g/day. (Research) (Research)
- Human pharmacokinetic studies report peak HMB blood levels within roughly 40–130 minutes, with faster absorption reported for some dissolved or free-acid formats than for calcium-HMB capsules. (Research) (Research)
- Older-adult trials show mixed findings, with some studies reporting physical-function or strength benefits and others finding little added effect beyond exercise. (Research) (Review)
- Clinical nutrition research has examined HMB in ICU, cancer, and cirrhosis-related malnutrition contexts, but evidence remains more limited and condition-specific. (Research) (Review)
- Regulatory authorities have reviewed HMB-related substances and proposed claims, but regulatory review should not be interpreted as proof of clinical benefit. (FDA) (EFSA)
Human Research Findings by Condition
Muscle Health
Human research on HMB and Muscle Health includes resistance-training trials, athlete studies, exercise-damage studies, and meta-analyses. Findings are more favorable in some untrained or early-training contexts, while trials and meta-analyses in trained athletes often report little or no added effect. (Review) (Review)
Key human study
Dose studied: 1.5 g/day and 3 g/day
Population: Young men beginning resistance training
Duration: 3 weeks
Researchers studied HMB during resistance training and reported that HMB partially reduced exercise-induced proteolysis or muscle-damage markers while supporting greater muscle-function gains in this early-training setting. The study helped establish 3 g/day as a frequently used research dose in later HMB trials. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 3 g/day
Population: Resistance-trained men
Duration: 9 weeks
A randomized trial in resistance-trained men found no clear benefit of HMB for strength or body composition outcomes. This trial supports the pattern that HMB effects may be smaller or absent in people who are already resistance-trained. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
Aging and Longevity Research
Research in Aging and Longevity Research has examined HMB in older adults with sarcopenia, low muscle mass, frailty, vitamin D insufficiency, or reduced activity. The evidence is mixed, with some trials reporting strength or function signals and meta-analyses showing that benefits are not consistent across all older-adult exercise settings. (Review) (Review)
Key human study
Dose studied: 3 g/day HMB plus vitamin D3
Population: Older adults with vitamin D insufficiency
Duration: 12 months
A randomized trial studied calcium-HMB plus vitamin D3 with and without resistance exercise in older adults. The study reported improvements in muscle strength and physical function in some groups, especially among participants not assigned to structured exercise. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 1.5 g/day calcium-HMB
Population: Women aged 65–79 years with low skeletal muscle index
Duration: 12-week intervention plus 12-week observation
A randomized double-blind factorial trial found that calcium-HMB produced only a small additive gait-performance effect and did not broadly enhance exercise effects on most measured outcomes. This study is useful because it shows that HMB does not consistently add to exercise in older adults with low muscle mass. (Research)
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Research)
Nutrition and Deficiencies
Human studies in Nutrition and Deficiencies have examined HMB in settings where muscle loss may occur during low activity, illness, or inadequate nutritional status. Evidence is strongest as a research theme rather than as a general nutritional conclusion, because results differ by population and clinical condition. (Research) (Review)
Key human study
Dose studied: Supplemental HMB in the trial protocol
Population: Healthy older adults undergoing bed rest
Duration: 10 days
A randomized trial reported that HMB preserved lean body mass during short-term bed rest in healthy older adults. This finding is relevant because bed rest is a controlled human model of inactivity-related muscle loss. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 3 g/day HMB
Population: Critically ill ICU patients
Duration: 10 days
A randomized trial in critically ill ICU patients did not find a significant reduction in muscle wasting over 10 days, although some amino acid metabolism markers changed. This shows that findings from controlled inactivity models do not necessarily translate to severe clinical illness. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Cancer Research
HMB has been studied in Cancer Research mostly through clinical nutrition studies and supplement combinations designed to examine body composition or muscle-related outcomes. Evidence remains limited because cancer populations, disease stages, nutrition formulas, and outcome measures differ substantially across studies. (Review)
Key human study
Dose studied: Varied across included studies
Population: Patients with cancer
Duration: Varied across included studies
A systematic review and meta-analysis reported limited evidence suggesting a possible beneficial effect of HMB supplementation on muscle mass and function in cancer populations. The conclusion should be interpreted cautiously because the review emphasized limited and heterogeneous evidence. (Review)
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Review)
Liver Health
HMB has been studied in Liver Health through clinical nutrition research involving cirrhosis and malnutrition. This evidence area is narrower than the exercise literature and usually involves HMB-enriched nutritional formulas rather than purified HMB alone. (Research)
Key human study
Dose studied: HMB-enriched oral nutritional supplement
Population: Patients with decompensated cirrhosis and malnutrition
Duration: Trial duration reported in the clinical publication
A randomized clinical trial studied an HMB-enriched oral nutritional supplement in patients with decompensated cirrhosis and malnutrition. This context is best interpreted as clinical nutrition research, not as direct evidence for isolated HMB in healthy individuals. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Diabetes and Glycemic Control
Human research in Diabetes and Glycemic Control is limited for HMB. The available evidence includes acute metabolic testing rather than long-term diabetes outcome trials. (Research)
Key human study
Dose studied: Acute HMB exposure during oral glucose testing
Population: Young and older men
Duration: Acute test session
A human study examined HMB during an oral glucose tolerance test to evaluate glucose and insulin kinetics. This study provides short-term metabolic information, but it does not establish long-term effects on diabetes risk, diabetes management, or glycemic control. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human HMB evidence includes small endogenous exposure estimates, single-dose pharmacokinetic studies, resistance-training trials, older-adult trials, and clinical nutrition studies. The research literature is centered on 1.5 g/day, 3 g/day, and 6 g/day supplemental exposures, while formulation studies often use 1 g single-dose comparisons. (Review) (Research)
0.2–0.4 g/day estimated endogenous production:
Humans produce HMB naturally during leucine metabolism, but estimated endogenous production is much lower than the gram-level doses used in supplementation trials. A review estimated that a 70 kg person produces roughly 0.2–0.4 g/day of HMB from normal leucine metabolism. This exposure is not a supplement dose; it is a background physiological estimate that helps distinguish normal metabolism from research-dose supplementation. The estimate also explains why HMB studies often use doses much higher than ordinary endogenous production. (Review)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This is an estimated physiological exposure, not a clinical trial dose.
1 g single-dose HMB pharmacokinetic exposure:
Human pharmacokinetic studies use 1 g HMB-equivalent single doses to compare blood exposure between formulations. In a 2024 crossover study, HMB-Ca dissolved in water reached peak plasma concentration at 43 ± 22 minutes, HMB-Ca capsules at 79 ± 40 minutes, and HMB-FA capsules at 78 ± 21 minutes. The same study reported that formulation affected absorption speed and peak concentration, while elimination kinetics were broadly similar across forms. These findings describe absorption and blood exposure, not long-term training or clinical outcomes. (Research)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Pharmacokinetic results describe blood exposure patterns, not functional benefit.
1.5 g/day supplemental HMB:
A randomized double-blind trial in older women with low skeletal muscle index used 1.5 g/day calcium-HMB in a factorial design with exercise. The study found only a small additive gait-performance effect and did not show broad enhancement of exercise effects on most outcomes. This lower supplemental dose is important because it represents a studied exposure below the more common 3 g/day dose. The findings suggest that lower-dose HMB does not consistently produce broad muscle or function changes when layered onto exercise. (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The study population was older women with low muscle mass, so findings may not generalize to athletes or younger adults.
1.5 g/day and 3 g/day supplemental HMB during resistance training:
An early resistance-training study in young men compared 1.5 g/day and 3 g/day HMB during a 3-week training period. The study reported reduced markers of exercise-induced proteolysis or muscle damage and greater muscle-function gains, helping establish HMB as a muscle-focused research ingredient. The higher dose became a common reference point in later trials and reviews. The short study duration and early-training population are important limitations when applying the findings to trained athletes. (Research)
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The clearest signal came from an early-training population rather than experienced lifters.
3 g/day supplemental HMB in trained resistance exercise:
A randomized trial in resistance-trained men used 3 g/day HMB for 9 weeks and reported no clear improvement in strength or body composition. This dose band is important because it shows that the most common research dose does not consistently produce benefits in trained populations. Meta-analytic evidence also reports trivial or no effects in trained or competitive athletes. These findings help explain why HMB evidence is more mixed in sports-performance contexts than in muscle-preservation contexts. (Research) (Review)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: Training status appears to be a major factor in study results.
3 g/day supplemental HMB in older-adult and sarcopenia contexts:
Older-adult studies commonly use 3 g/day HMB, often as calcium-HMB or in combination with vitamin D3. A 12-month trial of calcium-HMB plus vitamin D3 reported improvements in muscle strength and physical function in some older adults with vitamin D insufficiency. A sarcopenia trial reported that HMB combined with resistance exercise improved strength, physical performance, muscle quality, and inflammatory markers. However, reviews of older adults show that HMB does not consistently add benefit beyond exercise across all trials. (Research) (Research) (Review)
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Effects may depend on vitamin D status, baseline muscle condition, activity level, and whether exercise is included.
3 g/day supplemental HMB in clinical or catabolic illness contexts:
Clinical studies have used 3 g/day HMB in settings such as ICU-related muscle wasting. A randomized ICU trial did not significantly reduce muscle wasting over 10 days, although some amino acid metabolism markers changed. This finding contrasts with more favorable results from controlled bed-rest models and illustrates that severe illness may not respond the same way as inactivity alone. Clinical populations often include multiple overlapping drivers of muscle loss, including inflammation, immobility, nutrition status, and disease severity. (Research) (Review)
Result: No clear effect
Evidence strength: Limited
Notes / limitations: ICU outcomes are harder to interpret than exercise or bed-rest studies because illness severity varies.
6 g/day supplemental HMB:
Some resistance-training research has examined 6 g/day calcium-HMB, including dose-comparison work in men. Available summaries report no clear advantage of 6 g/day over 3 g/day in the studied resistance-training context. A study in experienced resistance-trained men using 3 g/day and 6 g/day reported no statistically significant effects on body composition, strength, or catabolic markers. This dose band is important because higher exposure has not consistently shown better outcomes in trained populations. (Review) (Research)
Result: Neutral overall findings
Evidence strength: Limited
Notes / limitations: Higher-dose findings are less extensive than the 3 g/day literature.
Key Takeaways from Human Research
- HMB has its strongest research identity in Muscle Health, especially resistance training, inactivity-related muscle loss, and aging-related muscle outcomes. (Review)
- Evidence is more favorable in some untrained, older, inactive, or catabolic settings than in trained athlete populations. (Review) (Review)
- 3 g/day is the most common supplemental dose in human trials, but lower and higher exposures have also been studied. (Research) (Research)
- HMB free acid and calcium-HMB differ in pharmacokinetic behavior, which may affect blood appearance timing but does not automatically prove different long-term outcomes. (Research) (Research)
- Older-adult trials show mixed results, with some positive findings in vitamin D insufficiency or sarcopenia contexts and less consistent additive effects when combined with exercise. (Research) (Review)
- Clinical nutrition contexts such as ICU, cancer, and cirrhosis remain more limited and should be interpreted separately from sports-nutrition studies. (Review) (Review)
Origin & Natural Occurrence
HMB originates in the body as a metabolite of leucine, an essential amino acid involved in protein metabolism. A review estimated that normal leucine metabolism produces approximately 0.2–0.4 g/day HMB in a 70 kg person. (Review)
HMB can also be consumed exogenously in supplement or nutritional-product forms. Human research commonly uses calcium-HMB, HMB free acid, or HMB-enriched oral nutritional formulas, depending on whether the study is focused on sports nutrition, pharmacokinetics, aging, or clinical nutrition. (Research) (Research)
Commercial HMB is generally supplied as a manufactured ingredient rather than as an isolated food component. FDA substance records identify HMB-related chemical names and synonyms, while FDA notification records include a dietary-ingredient notification involving an HMB-containing compound. (FDA) (FDA)
How It Behaves in the Body
In plain language, HMB is connected to muscle metabolism because it comes from leucine, an amino acid involved in protein turnover. Protein turnover means the body is constantly breaking down and rebuilding proteins, including muscle proteins. (Review)
Mechanistic reviews describe HMB as influencing pathways related to muscle protein breakdown and muscle protein synthesis. These pathways include cellular systems involved in protein degradation and signaling processes related to muscle repair and adaptation. (Review)
Human studies often measure outcomes such as lean mass, strength, physical function, markers of muscle damage, or muscle protein synthesis. These outcomes do not all move in the same direction across studies, which is one reason the evidence is mixed. (Review) (Review)
What is well established is that HMB is a leucine-derived metabolite and that oral HMB can raise circulating HMB levels after intake. What is less settled is whether those exposure changes reliably translate into larger strength, muscle-mass, or function changes across all populations. (Research) (Review)
Absorption & Delivery Formats
Oral immediate-release: Oral calcium-HMB and HMB free acid have both been studied in human pharmacokinetic research. In a 2024 crossover study, 1 g HMB-Ca dissolved in water peaked at 43 ± 22 minutes, while HMB-Ca capsules and HMB-FA capsules peaked at 79 ± 40 minutes and 78 ± 21 minutes, respectively. (Research)
Oral extended-release: Extended-release HMB is not a major format in the human evidence set reviewed here. Most human research uses conventional oral capsules, dissolved HMB-Ca, HMB free acid formats, or HMB-enriched oral nutritional formulas. (Research) (Research)
Sublingual: One pharmacokinetic study included an HMB free acid gel condition held sublingually for 15 seconds before swallowing, but that design does not establish a separate long-term sublingual clinical evidence base. In that study, HMB free acid gel peaked faster than calcium-HMB capsules, while clinical outcome evidence still comes mainly from oral supplementation trials. (Research)
Transdermal: Transdermal HMB is not a major human research delivery format in the evidence reviewed here. Published human studies relevant to HMB nutrition, exercise, aging, and pharmacokinetics primarily evaluate oral forms. (Research) (Research)
Injectable / IV: Injectable or IV HMB is not a standard human supplement research format in the evidence reviewed here. Human studies relevant to nutrition, exercise, and aging primarily use oral HMB or HMB-containing oral nutritional products. (Research) (Research)
Quick Facts at a Glance
Onset (reported): Blood HMB begins rising after oral intake and typically reaches peak levels within about 40–130 minutes, depending on formulation and study design. This timing describes blood exposure, not an immediate strength, performance, or muscle-mass effect. Functional outcomes in HMB trials are usually measured over weeks or months. (Research) (Research)
Time to peak (Tmax): Human pharmacokinetic studies report that oral HMB generally reaches peak blood levels within roughly 40–130 minutes, depending on formulation. In a 1 g crossover study, HMB-Ca dissolved in water peaked at 43 ± 22 minutes, HMB-Ca capsules at 79 ± 40 minutes, and HMB-FA capsules at 78 ± 21 minutes. An earlier pharmacokinetic study reported faster peak timing for HMB free acid gel than for calcium-HMB capsules. (Research) (Research)
Half-life (t½): Human single-dose pharmacokinetic evidence suggests that HMB elimination is measured in hours, not days. One pharmacokinetic study reported half-life values of roughly 2.5–3.2 hours, depending on formulation. The practical interpretation is that formulation can affect absorption speed and blood exposure timing, but long-term muscle or performance outcomes still require outcome trials. (Research)
Typical duration: Resistance-training studies range from short 3-week interventions to multi-week trials, while older-adult studies include 12-week and 12-month designs. Study duration matters because short trials may capture muscle-damage markers or early training adaptation, while longer trials are better suited for strength, function, and body-composition outcomes. (Research) (Research)
Absorption routes studied: Oral ingestion is the main absorption route studied in humans. The evidence set includes calcium-HMB capsules, HMB-Ca dissolved in water, HMB free acid formats, and HMB-enriched oral nutritional supplements. (Research) (Research)
Formulation differences: Formulation affects HMB absorption speed and peak exposure. In the 2024 crossover study, HMB-Ca dissolved in water reached peak plasma concentration faster than HMB-Ca capsules or HMB-FA capsules, while elimination kinetics were broadly similar across forms. Earlier pharmacokinetic work also reported faster peak appearance for HMB free acid gel than for calcium-HMB capsules. (Research) (Research)
Variability drivers: Study results vary by training status, age, baseline muscle condition, disease state, co-interventions, vitamin D status, and whether exercise is included. Meta-analyses show more neutral findings in trained athletes and more mixed findings in older or clinical populations. (Review) (Review)
Tolerance / adaptation: Human safety summaries report that HMB has generally been well tolerated in studied settings, including research using 3 g/day. Tolerance in the sense of diminishing effect over time has not been clearly established as a major human research finding. (Research) (Review)
Evidence strength snapshot: HMB has a moderate-sized human evidence base, but confidence differs by context. The strongest research concentration is in muscle-related outcomes, while results in trained athletes and severe clinical illness are less consistent. (Review) (Review)
Other Physiological Contexts Studied (If Applicable)
- HMB has been studied acutely during oral glucose tolerance testing in young and older men, but this does not establish long-term effects on diabetes outcomes. (Research)
- HMB research in cancer populations has focused mainly on muscle mass, function, and nutrition-related outcomes rather than direct cancer-disease outcomes. (Review)
- HMB-enriched formulas have been studied in cirrhosis-related malnutrition, but this format includes broader nutritional support rather than isolated HMB alone. (Research)
- ICU studies examine muscle wasting and clinical nutrition during severe illness, and their findings should not be generalized directly to exercise performance. (Research) (Review)
Safety, Interactions & Regulation
Human safety data summarized across nine studies evaluated 3 g/day HMB for 3–8 weeks in men and women, young and older adults, and exercising and non-exercising participants. The safety analysis assessed blood chemistry, hematology, emotional-profile measures, and health-related questionnaires. (Research)
Longer-duration older-adult research using calcium-HMB plus vitamin D3 provides human exposure data over 12 months. This combination evidence is useful for longer-term context, but it does not isolate HMB from vitamin D3. (Research)
Adverse effects in HMB studies are generally not the main limiting factor in the evidence base; the larger limitation is that efficacy findings vary by population and outcome. A sports-nutrition position stand summarized available data and stated that chronic oral HMB-Ca and HMB-FA appear safe in humans up to at least one year, based on the available literature. (Review)
Potential interaction categories are not well characterized in the cited human HMB trials. Because HMB is often studied in older adults, ICU patients, cancer populations, or people with liver disease, clinical context and co-administered nutrition or exercise programs are important when interpreting safety data. (Review) (Research)
Population cautions are most relevant for people with serious illness, malnutrition, cancer, cirrhosis, or ICU-level conditions because these studies involve medically complex settings. Evidence from those populations should be interpreted as clinical nutrition research rather than general consumer guidance. (Review) (Research)
In the United States, FDA substance-registration records list HMB-related chemical identities and synonyms. (FDA) FDA New Dietary Ingredient notification records include a notification involving beta-hydroxy-beta-methylbutyrate-L-arginine. (FDA)
In the European Union, EFSA reviewed proposed health claims related to beta-hydroxy beta-methylbutyrate monohydrate and evaluated claims related to muscle and resistance-training outcomes. (EFSA) EFSA’s claim evaluation should be interpreted as a regulatory scientific assessment of proposed claims, not as a general clinical recommendation. (EFSA)
Evidence Overview
The human evidence base for HMB is strongest in Muscle Health, especially resistance-training, aging-related muscle function, and muscle-preservation contexts, but findings are not uniform across populations. Meta-analyses suggest that benefits are more plausible in untrained, older, inactive, or clinically vulnerable groups than in trained and competitive athletes. In trained athletes, pooled evidence reports no clear effect on strength or body composition. Confidence remains moderate rather than strong because studies differ by training status, age, formulation, dose, co-interventions, and outcome measures. (Review) (Review) (Review)
The exercise literature includes early resistance-training trials, trained-athlete trials, and meta-analyses that separate results by training status. This pattern is important because HMB can appear more promising in beginners or catabolic states than in trained athletes who are already adapted to resistance training. (Research) (Research)
The aging literature includes trials in older adults with low muscle mass, sarcopenia, vitamin D insufficiency, or inactivity-related muscle loss. Some studies report meaningful functional or strength signals, but systematic reviews show inconsistency across body composition, gait speed, handgrip strength, and performance outcomes. (Research) (Review)
Clinical nutrition research has examined HMB in ICU, cancer, and liver-disease contexts, but these areas are less mature than the exercise and aging literature. The ICU evidence includes neutral findings for muscle wasting and broader clinical outcomes, while cancer and cirrhosis studies often involve complex nutritional formulas or heterogeneous patient populations. (Research) (Review) (Research)
Pharmacokinetic studies strengthen understanding of HMB exposure because they show that calcium-HMB and HMB free acid can differ in plasma appearance. In a 1 g crossover study, HMB-Ca dissolved in water peaked at 43 ± 22 minutes, HMB-Ca capsules at 79 ± 40 minutes, and HMB-FA capsules at 78 ± 21 minutes. These timing differences should not be treated as proof of superior clinical outcomes unless outcome trials directly support that interpretation. (Research)
Future research would strengthen confidence by using larger trials, longer follow-up, clearer subgroup definitions, direct formulation comparisons, and consistent outcome measures. The most useful future trials would separate untrained, trained, older, sarcopenic, and clinical populations rather than combining them into broad summaries. (Review) (Review)
Evidence Confidence Classification
The overall human evidence for HMB is Moderate / Mixed, based on multiple randomized trials and meta-analyses showing muscle-related research signals but inconsistent results across training status, age, and clinical context. (Review) (Review)
The evidence is stronger for the fact that HMB has been studied extensively in Muscle Health than for a single uniform effect across all users. Human trials and reviews support the view that results differ between untrained individuals, trained athletes, older adults, and clinical populations. (Review) (Review)
Mechanistic plausibility is supported by HMB’s role as a leucine metabolite involved in muscle protein turnover, but mechanistic plausibility does not eliminate the need for population-specific outcome trials. (Review) Pharmacokinetic evidence is useful for formulation interpretation, but clinical confidence depends on whether measured exposure changes translate into functional outcomes. (Research)
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Leucine
- Essential amino acids
- Branched-chain amino acids
- Creatine monohydrate
- Protein powders
- Whey protein
- Vitamin D3
- Omega-3 fatty acids
- Glutamine
- Arginine
- Collagen peptides
Medical / pharma comparator categories:
- Medical nutrition formulas
- Protein-energy supplementation strategies
- Physical rehabilitation programs
- Resistance-training interventions
- Sarcopenia-focused clinical nutrition approaches
Combination Context
HMB + Vitamin D3:
HMB combined with vitamin D3 has been studied in older adults with vitamin D insufficiency. A 12-month randomized trial reported improvements in strength and physical function in some groups, but the combination makes it difficult to attribute all effects to HMB alone. (Research)
HMB + Resistance Exercise:
HMB has frequently been studied alongside resistance exercise because the research question often concerns training adaptation, muscle damage, or muscle preservation. Evidence is mixed: some older-adult and early-training studies report positive signals, while reviews in trained or older exercise populations show limited additional benefit. (Research) (Review)
HMB + Oral Nutritional Supplements:
HMB-enriched oral nutritional supplements have been studied in clinical nutrition settings such as cirrhosis-related malnutrition. These studies evaluate broader nutrition support rather than isolated HMB, so conclusions should remain specific to the formula and population studied. (Research)
HMB + Arginine / Glutamine Context:
Some HMB research in clinical nutrition has used HMB in combination contexts rather than as a standalone ingredient. This is relevant because combination formulas may address energy, amino acid intake, or disease-related nutrition status at the same time as HMB exposure. (Review)
FAQ
What is HMB?
HMB is β-hydroxy β-methylbutyrate, a metabolite formed from the amino acid leucine. It is produced naturally in small amounts during human leucine metabolism. (Review) HMB is also studied as an oral supplemental ingredient in calcium-HMB and HMB free acid forms. (Research)
What does human research study HMB for?
Human research studies HMB mainly for Muscle Health, including resistance-training adaptation, muscle damage markers, lean mass, strength, and physical function. (Review) It is also studied in older adults, bed-rest models, ICU patients, cancer-related nutrition contexts, and cirrhosis-related malnutrition. (Research) (Review)
What are the best-supported uses?
The best-supported research area for HMB is muscle-related human research, especially contexts involving untrained people, older adults, inactivity, or muscle-loss risk. (Review) The evidence is not equally strong across all groups, because trained-athlete meta-analyses often report no clear strength or body-composition benefit. (Review)
Where is evidence mixed or limited?
Evidence is mixed in trained athletes, older adults exercising regularly, ICU patients, and clinical nutrition contexts. Meta-analyses in trained and competitive athletes report no clear effect on strength or body composition. (Review) ICU and cancer evidence remains limited and condition-specific. (Review) (Review)
How quickly does HMB act?
HMB can appear in blood within the first hour after oral intake, depending on formulation. In a 1 g crossover study, HMB-Ca dissolved in water peaked at 43 ± 22 minutes, while HMB-Ca capsules and HMB-FA capsules peaked at about 78–79 minutes. (Research) Functional outcomes such as strength, lean mass, or physical performance are usually studied over weeks or months rather than minutes or hours. (Research) (Research)
What affects absorption and variability?
Formulation affects HMB blood exposure patterns, with studies comparing calcium-HMB, HMB free acid, capsules, and dissolved forms. (Research) Study outcomes also vary by training status, age, baseline muscle condition, illness severity, exercise program, and co-interventions. (Review) (Review)
Is tolerance reported?
Human studies generally report HMB as well tolerated in studied contexts, including research using 3 g/day for 3–8 weeks. (Research) Tolerance in the sense of diminishing effect over time is not clearly established as a major finding in the reviewed human evidence. (Review)
Why do studies disagree?
HMB studies disagree partly because they include different populations, such as beginners, trained athletes, older adults, bed-rest participants, and ICU patients. (Review) Training status appears especially important, because untrained populations show more favorable signals than trained or competitive athletes in meta-analyses. (Review) (Review)
What ingredients is HMB commonly combined with and why?
HMB is commonly studied with resistance exercise because many trials focus on muscle adaptation, strength, or muscle damage. (Research) HMB is also studied with vitamin D3 in older adults and in oral nutrition formulas for clinical populations. (Research) (Research)
What foods naturally contain HMB?
HMB is primarily discussed in human research as a leucine metabolite rather than as a major dietary compound. The body produces small amounts from leucine metabolism, and those endogenous amounts are lower than the gram-level doses used in supplement trials. (Review)
How is HMB regulated?
In the United States, FDA substance-registration records list HMB-related chemical names and synonyms. (FDA) FDA New Dietary Ingredient notification records include a notification involving beta-hydroxy-beta-methylbutyrate-L-arginine. (FDA) In the European Union, EFSA reviewed proposed HMB-related health claims and evaluated the scientific substantiation for those claims. (EFSA)
Resources
- HMB and skeletal muscle review — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC5566641/
- Resistance training meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/19387395/
- Trained athletes meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/29249685/
- Older adults physical training review — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC6769498/
- Bed-rest trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/23514626/
- HMB plus vitamin D3 trial — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC7566440/
- HMB pharmacokinetic formulation study — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC10987370/
- HMB free-acid and calcium-salt pharmacokinetic study — PubMed — https://pubmed.ncbi.nlm.nih.gov/21134325/
- Cancer systematic review — PubMed — https://pubmed.ncbi.nlm.nih.gov/35301826/
- EFSA HMB health-claims opinion — EFSA — https://www.efsa.europa.eu/en/efsajournal/pub/2227
- FDA substance record — FDA GSRS — https://precision.fda.gov/ginas/app/ui/substances/0c88e5b6-838f-4d95-b758-977be147375e
- FDA NDI status report — FDA — https://www.fda.gov/media/160660/download
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
